RhoA and RhoC -siRNA Inhibit the Proliferation and Invasiveness Activity of Human Gastric Carcinoma by Rho/PI3K/Akt Pathway

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2007 Jul 31

PMID 17659701

Citations 23

Authors

Hua-Wen Sun

Shi-Lun Tong

Jie He

Qi Wang

Li Zou

Shu-Jing Ma

Hai-Yan Tan

Jian-Fei Luo

Hong-Xue Wu

Affiliations

Soon will be listed here.

Abstract

Aim: To evaluate the effects of adenovirus-mediated gene transfer of RhoA siRNA and RhoC siRNA on proliferation and invasion of SGC7901 cells by Rho/PI3K/Akt pathway.

Methods: Plasmid of RhoA siRNA and RhoC siRNA were constructed and transfected into SGC7901 cells. siRNA and LY294002 (PI3K inhibitor) were designed as the control group. The mRNA and protein expressions of RhoA and RhoC were respectively detected with RT-PCR and western blotting. In order to find out the changes of proliferation and invasion power of SGC7901 cell lines, we analyzed the data by MTT, Boyden chamber and evaluated apoptosis of cell with flow cytometry. We treated BALB/C nude mice with RhoA and RhoC-siRNA, and tumor control rate (%) in nude mice was calculated.

Results: RhoA and RhoC siRNA transfections specifically down-regulated the corresponding mRNA and protein levels in SGC7901 Cells. The experiment of permeated artificial basal membrane showed that the invasion power of SGC7901 cell lines are on the decline after treatment of Ad-RhoA and RhoC-siRNA (12.64 +/-3.27 vs 87.38 +/- 17.38, P < 0.05). The values of 490 nm wavelength light absorption were different in the five groups. The number of alive cells in the group of RhoA and RhoC-siRNA was lower than others in the 6(th) d (0.71 +/- 0.01 vs 3.82 +/- 0,11 P < 0.05). The apoptosis rate of transfected RhoA and RhoC-siRNA group with FACS were 19.07% +/- 1.78 and there were significant differences between treated and control groups (19.07 +/- 1.78% vs 1.23 +/- 0.11%, P < 0.01). The tumor transplantation experiment in BALB/C nude mice showed intratumoral injection of RhoA or RhoC siRNA can inhibit tumor growth.

Conclusion: RhoA and RhoC siRNA gene therapy mediated by adenovirus may be useful for inhibiting growth and invasion of SGC7901 through a PI3K/Akt pathway. These results provide a novel therapeutic target in preventing gastric cancer cell invasion and metastasis.

Citing Articles

siRNA-based strategies to combat drug resistance in gastric cancer.

Khaleel A, Alshahrani M, Rizaev J, Malathi H, Devi S, Pramanik A Med Oncol. 2024; 41(11):293.

PMID: 39428440 DOI: 10.1007/s12032-024-02528-w.

Oncolytic virus: A catalyst for the treatment of gastric cancer.

Wang J, Du L, Chen X Front Oncol. 2022; 12:1017692.

PMID: 36505792 PMC: 9731121. DOI: 10.3389/fonc.2022.1017692.

Activation of RhoC by regulatory ubiquitination is mediated by LNX1 and suppressed by LIS1.

Kholmanskikh S, Singh S, Ross M Sci Rep. 2022; 12(1):16493.

PMID: 36192543 PMC: 9529947. DOI: 10.1038/s41598-022-19740-1.

Mammographic density: intersection of advocacy, science, and clinical practice.

Tossas-Milligan K, Shalabi S, Jones V, Keely P, Conklin M, Eliceiri K Curr Breast Cancer Rep. 2020; 11(3):100-110.

PMID: 33312342 PMC: 7728377. DOI: 10.1007/s12609-019-00316-4.

Local delivery of RhoA siRNA by PgP nanocarrier reduces inflammatory response and improves neuronal cell survival in a rat TBI model.

Macks C, Jeong D, Lee J Nanomedicine. 2020; 32:102343.

PMID: 33259960 PMC: 8714129. DOI: 10.1016/j.nano.2020.102343.

References

Ikoma T, Takahashi T, Nagano S, Li Y, Ohno Y, Ando K . A definitive role of RhoC in metastasis of orthotopic lung cancer in mice. Clin Cancer Res. 2004; 10(3):1192-200. DOI: 10.1158/1078-0432.ccr-03-0275. View

Xu J, Langefeld C, Zheng S, Gillanders E, Chang B, Isaacs S . Interaction effect of PTEN and CDKN1B chromosomal regions on prostate cancer linkage. Hum Genet. 2004; 115(3):255-62. DOI: 10.1007/s00439-004-1144-4. View

Liu N, Bi F, Pan Y, Sun L, Xue Y, Shi Y . Reversal of the malignant phenotype of gastric cancer cells by inhibition of RhoA expression and activity. Clin Cancer Res. 2004; 10(18 Pt 1):6239-47. DOI: 10.1158/1078-0432.CCR-04-0242. View

Wheeler A, Ridley A . Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. Exp Cell Res. 2004; 301(1):43-9. DOI: 10.1016/j.yexcr.2004.08.012. View

Simpson K, Dugan A, Mercurio A . Functional analysis of the contribution of RhoA and RhoC GTPases to invasive breast carcinoma. Cancer Res. 2004; 64(23):8694-701. DOI: 10.1158/0008-5472.CAN-04-2247. View

Walker K, Olson M . Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr Opin Genet Dev. 2005; 15(1):62-8. DOI: 10.1016/j.gde.2004.11.001. View

Pille J, Denoyelle C, Varet J, Bertrand J, Soria J, Opolon P . Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther. 2005; 11(2):267-74. DOI: 10.1016/j.ymthe.2004.08.029. View

Erschbamer M, Hofstetter C, Olson L . RhoA, RhoB, RhoC, Rac1, Cdc42, and Tc10 mRNA levels in spinal cord, sensory ganglia, and corticospinal tract neurons and long-lasting specific changes following spinal cord injury. J Comp Neurol. 2005; 484(2):224-33. DOI: 10.1002/cne.20471. View

Meili R, Sasaki A, Firtel R . Rho Rocks PTEN. Nat Cell Biol. 2005; 7(4):334-5. DOI: 10.1038/ncb0405-334. View

10.

Schichor C, Kerkau S, Visted T, Martini R, Bjerkvig R, Tonn J . The brain slice chamber, a novel variation of the Boyden Chamber Assay, allows time-dependent quantification of glioma invasion into mammalian brain in vitro. J Neurooncol. 2005; 73(1):9-18. DOI: 10.1007/s11060-004-3341-3. View

11.

Wang Z, Xu H, Jiang L, Zhou X, Lu C, Zhang X . Positive association of RhoC gene overexpression with tumour invasion and lymphatic metastasis in gastric carcinoma. Chin Med J (Engl). 2005; 118(6):502-4. View

12.

Lin M, DiVito M, Merajver S, Boyanapalli M, van Golen K . Regulation of pancreatic cancer cell migration and invasion by RhoC GTPase and caveolin-1. Mol Cancer. 2005; 4(1):21. PMC: 1173138. DOI: 10.1186/1476-4598-4-21. View

13.

Yao H, Dashner E, van Golen C, van Golen K . RhoC GTPase is required for PC-3 prostate cancer cell invasion but not motility. Oncogene. 2005; 25(16):2285-96. DOI: 10.1038/sj.onc.1209260. View

14.

Castiblanco G A, Pires N Y, Wistuba O I, Riquelme S E, Andrade M L, Corvalan R A . [Pathogenic role of PTEN tumor suppressor gene in ovarian cancer associated to endometriosis]. Rev Med Chil. 2006; 134(3):271-8. DOI: 10.4067/s0034-98872006000300001. View

15.

Bilbao C, Rodriguez G, Ramirez R, Falcon O, Leon L, Chirino R . The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer. Int J Cancer. 2006; 119(3):563-70. DOI: 10.1002/ijc.21862. View

16.

Zhang Y, Zhang B . D4-GDI, a Rho GTPase regulator, promotes breast cancer cell invasiveness. Cancer Res. 2006; 66(11):5592-8. DOI: 10.1158/0008-5472.CAN-05-4004. View

17.

Faried A, Faried L, Kimura H, Nakajima M, Sohda M, Miyazaki T . RhoA and RhoC proteins promote both cell proliferation and cell invasion of human oesophageal squamous cell carcinoma cell lines in vitro and in vivo. Eur J Cancer. 2006; 42(10):1455-65. DOI: 10.1016/j.ejca.2006.02.012. View

18.

Kandpal R . Rho GTPase activating proteins in cancer phenotypes. Curr Protein Pept Sci. 2006; 7(4):355-65. DOI: 10.2174/138920306778018025. View

19.

Pan Q, Bao L, Teknos T, Merajver S . Targeted disruption of protein kinase C epsilon reduces cell invasion and motility through inactivation of RhoA and RhoC GTPases in head and neck squamous cell carcinoma. Cancer Res. 2006; 66(19):9379-84. PMC: 4383316. DOI: 10.1158/0008-5472.CAN-06-2646. View

20.

Bellovin D, Simpson K, Danilov T, Maynard E, Rimm D, Oettgen P . Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma. Oncogene. 2006; 25(52):6959-67. DOI: 10.1038/sj.onc.1209682. View